Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota

Gastroenterology

Volumn 155, Issue 5, 2018, Pages 1495-1507.e15

  McDonald, Julie A K ^a   Mullish, Benjamin H ^a   Pechlivanis, Alexandros ^a   Liu, Zhigang ^a   Brignardello, Jerusa ^a   Kao, Dina ^b   Holmes, Elaine ^a   Li, Jia V ^a   Clarke, Thomas B ^a   Thursz, Mark R ^a   Marchesi, Julian R ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bacteria; Gut Microbiome; Pathogen; Stool Transplant

Indexed keywords

DEOXYCHOLIC ACID; RNA 16S; SUCCINIC ACID; TAUROCHOLIC ACID; VALERIC ACID; BILE ACID; CLINDAMYCIN; GLYCEROL TRIVALERATE; TRIACYLGLYCEROL; VALERIC ACID DERIVATIVE;

ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; COMPREHENSION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; GENE SEQUENCE; GERMINATION; GROWTH INHIBITION; HUMAN; INTESTINE FLORA; MASS SPECTROMETRY; MICROBIAL COMMUNITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VEGETATIVE GROWTH; ANIMAL; BACTERIAL SPORE; C57BL MOUSE; CHEMISTRY; CLOSTRIDIUM INFECTION; DRUG EFFECT; FECES; FEMALE; GROWTH, DEVELOPMENT AND AGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; BILE ACIDS AND SALTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GASTROINTESTINAL MICROBIOME; MAGNETIC RESONANCE SPECTROSCOPY; MICE, INBRED C57BL; SPORES, BACTERIAL; TRIGLYCERIDES; VALERATES;

EID: 85055768814     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.07.014     Document Type: Article

References (76)

1. Mitu-Pretorian, O.M., Forgacs, B., Qumruddin, A., et al. Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc 42 (2010), 2631–2633.
2. Ma, G.K., Brensinger, C.M., Wu, Q., et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 167 (2017), 152–158.
3. van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
4. Petrof, E.O., Gloor, G.B., Vanner, S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome, 1, 2013, 3.
5. Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190 (2008), 2505–2512.
6. Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E. Jr., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun, 5, 2014, 3114.
7. Weingarden, A.R., Chen, C., Bobr, A., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306 (2014), G310–G319.
8. Ferreyra, J.A., Wu, K.J., Hryckowian, A.J., et al. Gut microbiota-produced succinate promotes C difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16 (2014), 770–777.
9. Ott, S.J., Waetzig, G.H., Rehman, A., et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 152 (2017), 799–811.e7.
10. De Filippo, C., Cavalieri, D., Di Paola, M., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
11. Morrison, D.J., Preston, T., Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7 (2016), 189–200.
12. McDonald, J.A.K., In vitro models of the human microbiota and microbiome. Emerg Top Life Sci 1 (2017), 373–384.
13. Macfarlane, G.T., Macfarlane, S., Models for intestinal fermentation: association between food components, delivery systems, bioavailability and functional interactions in the gut. Curr Opin Biotechnol 18 (2007), 156–162.
14. McDonald, J.A., Schroeter, K., Fuentes, S., et al. Evaluation of microbial community reproducibility, stability and composition in a human distal gut chemostat model. J Microbiol Methods 95 (2013), 167–174.
15. Van den Abbeele, P., Grootaert, C., Marzorati, M., et al. Microbial community development in a dynamic gut model is reproducible, colon region specific, and selective for Bacteroidetes and Clostridium cluster IX. Appl Environ Microbiol 76 (2010), 5237–5246.
16. Freeman, J., Baines, S.D., Jabes, D., et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56 (2005), 717–725.
17. Baines, S.D., O'Connor, R., Saxton, K., et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 62 (2008), 1078–1085.
18. Chilton, C.H., Crowther, G.S., Freeman, J., et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 69 (2014), 451–462.
19. Chilton, C.H., Crowther, G.S., Baines, S.D., et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C difficile infection. J Antimicrob Chemother 69 (2014), 697–705.
20. Meader, E., Mayer, M.J., Steverding, D., et al. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22 (2013), 25–30.
21. Chilton, C.H., Crowther, G.S., Spiewak, K., et al. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection. J Antimicrob Chemother 71 (2016), 975–985.
22. Freeman, J., Baines, S.D., Saxton, K., et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 60 (2007), 83–91.
23. Mullish, B.H., Marchesi, J.R., Thursz, M.R., et al. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. QJM 108 (2015), 355–359.
24. Illumina. 16S metagenomic sequencing library preparation (part #15044223 Rev. B); 2013. Available at: https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf. 2017. Accessed December 17, 2017.
25. 1H NMR metabolomics data. Anal Chem 78 (2006), 4430–4442.
26. Sarafian, M.H., Lewis, M.R., Pechlivanis, A., et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem 87 (2015), 9662–9670.
27. Kao, D., Roach, B., Silva, M., et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318 (2017), 1985–1993.
28. Garcia-Villalba, R., Gimenez-Bastida, J.A., Garcia-Conesa, M.T., et al. Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J Sep Sci 35 (2012), 1906–1913.
29. Winston, J.A., Thanissery, R., Montgomery, S.A., et al. Cefoperazone-treated mouse model of clinically-relevant Clostridium difficile strain R20291. J Vis Exp, 118, 2016, 10.3791/54850.
30. Wolfer A. SANTA-App: interactive package for Short AsyNchronous Time-series Analysis (SANTA) in R, implemented in Shiny, 2017. Available at: https://github.com/adwolfer/SANTA-App. 2017. Accessed December 17, 2017.
31. Le Cao K, Rohart F, Gonzalez I, et al. mixOmics: Omics Data Integration Project. R package version 6.1.2., 2017. Available at: https://CRAN.R-project.org/package=mixOmics. 2017. Accessed December 17, 2017.
32. Schwartz, B., The effect of temperature on the rate of hydrolysis of triglycerides by pancreatic lipase. J Gen Physiol 27 (1943), 113–118.
33. Neis, E.P., Dejong, C.H., Rensen, S.S., The role of microbial amino acid metabolism in host metabolism. Nutrients 7 (2015), 2930–2946.
34. Barker, H.A., D'Ari, L., Kahn, J., Enzymatic reactions in the degradation of 5-aminovalerate by Clostridium aminovalericum. J Biol Chem 262 (1987), 8994–9003.
35. Seto, B., Stadtman, T.C., Purification and properties of proline reductase from Clostridium sticklandii. J Biol Chem 251 (1976), 2435–2439.
36. Hodgins, D.S., Abeles, R.H., Studies of the mechanism of action of D-proline reductase: the presence on covalently bound pyruvate and its role in the catalytic process. Arch Biochem Biophys 130 (1969), 274–285.
37. Seto, B., The Stickland reaction. Knowles, C.J., (eds.) Diversity of bacterial respiratory systems, Vol II, 1980, CRC Press, Boca Raton, FL, 49–64.
38. Buckel, W., Unusual enzymes involved in five pathways of glutamate fermentation. Appl Microbiol Biotechnol 57 (2001), 263–273.
39. Savidge T, Dann S. Methods and uses for metabolic profiling for Clostridium difficile infection. PCT/US2012/064218, 2013.
40. Fletcher, J.R., Erwin, S., Lanzas, C., et al. Shifts in the gut metabolome and Clostridium difficile transcriptome throughout colonization and infection in a mouse model. mSphere, 3, 2018, 10.1128/mSphere.00089-18.
41. Bornstein, B.T., Barker, H.A., The energy metabolism of Clostridium kluyveri and the synthesis of fatty acids. J Biol Chem 172 (1948), 659–669.
42. Borody, T.J., Khoruts, A., Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9 (2011), 88–96.
43. Louis, P., Flint, H.J., Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 19 (2017), 29–41.
44. Wilcox, M.H., Shetty, N., Fawley, W.N., et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 55 (2012), 1056–1063.
45. Waslawski, S., Lo, E.S., Ewing, S.A., et al. Clostridium difficile ribotype diversity at six health care institutions in the United States. J Clin Microbiol 51 (2013), 1938–1941.
46. Davies, K.A., Longshaw, C.M., Davis, G.L., et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14 (2014), 1208–1219.
47. Huang, H., Fang, H., Weintraub, A., et al. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 15 (2009), 1170–1173.
48. Hawkey, P.M., Marriott, C., Liu, W.E., et al. Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an underrecognized problem in Asia?. J Clin Microbiol 51 (2013), 3308–3313.
49. Dawson, L.F., Valiente, E., Donahue, E.H., et al. Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants. PLoS One, 6, 2011, e25754.
50. Allison, C., McFarlan, C., MacFarlane, G.T., Studies on mixed populations of human intestinal bacteria grown in single-stage and multistage continuous culture systems. Appl Environ Microbiol 55 (1989), 672–678.
51. Duncan, S.H., Scott, K.P., Ramsay, A.G., et al. Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. Appl Environ Microbiol 69 (2003), 1136–1142.
52. McDonald, J.A., Schroeter, K., Fuentes, S., et al. Evaluation of microbial community reproducibility, stability and composition in a human distal gut chemostat model. J Microbiol Methods 95 (2013), 167–174.
53. Freeman, J., Baines, S.D., Saxton, K., et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 60 (2007), 83–91.
54. Freeman, J., O'Neill, F.J., Wilcox, M.H., Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 52 (2003), 96–102.
55. Crowther, G.S., Chilton, C.H., Todhunter, S.L., et al. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. J Antimicrob Chemother 69 (2014), 2137–2147.
56. Miles, A.A., Misra, S.S., Irwin, J.O., The estimation of the bactericidal power of the blood. J Hyg (Lond) 38 (1938), 732–749.
57. Liu, C.M., Aziz, M., Kachur, S., et al. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol, 12, 2012, 56.
58. Kozich, J.J., Westcott, S.L., Baxter, N.T., et al. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79 (2013), 5112–5120.
59. Wang, Q., Garrity, G.M., Tiedje, J.M., et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73 (2007), 5261–5267.
60. Oksanen J, Blanchet FG, Friendly M, et al. Vegan: community ecology package. R package version 2.4–3, 2017. Available at: https://CRAN.R-project.org/package=vegan. 2017. Accessed December 17, 2017.
61. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2015. Available at: https://www.R-project.org/. 2017. Accessed December 17, 2017.
62. Rudis B. streamgraph: streamgraph is an htmlwidget for building streamgraph visualizations. R package version 0.8.1, 2015. Available at: http://github.com/hrbrmstr/streamgraph. 2017. Accessed December 17, 2017.
63. Beckonert, O., Keun, H.C., Ebbels, T.M., et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2 (2007), 2692–2703.
64. 1H NMR data sets. Anal Chem 77 (2005), 1282–1289.
65. Liu, Z., Wang, L., Zhang, L., et al. Metabolic characteristics of 16HBE and A549 cells exposed to different surface modified gold nanorods. Adv Healthc Mater 5 (2016), 2363–2375.
66. Dai, H., Xiao, C., Liu, H., et al. Combined NMR and LC-DAD-MS analysis reveals comprehensive metabonomic variations for three phenotypic cultivars of Salvia Miltiorrhiza Bunge. J Proteome Res 9 (2010), 1565–1578.
67. Sangster, T., Major, H., Plumb, R., et al. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131 (2006), 1075–1078.
68. Veselkov, K.A., Vingara, L.K., Masson, P., et al. Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem 83 (2011), 5864–5872.
69. Chang W, Cheng J, Allaire JJ, et al. Shiny: web application framework for R. R package version 1.0.3, 2017. Available at: https://CRAN.R-project.org/package=shiny. 2017. Accessed December 17, 2017.
70. Wolfer A. SANTA-App: Interactive package for Short AsyNchronous Time-series Analysis (SANTA) in R, implemented in shiny, 2017. Available at: https://github.com/adwolfer/SANTA-App. 2017. Accessed December 17, 2017.
71. Gratton, J., Phetcharaburanin, J., Mullish, B.H., et al. Optimized sample handling strategy for metabolic profiling of human feces. Anal Chem 88 (2016), 4661–4668.
72. Le Cao K, Rohart F, Gonzalez I, et al. MixOmics: omics data integration project. R package version 6.1.2, 2017. Available at: https://CRAN.R-project.org/package=mixOmics. 2017. Accessed December 17, 2017.
73. Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190 (2008), 2505–2512.
74. Thanissery, R., Winston, J.A., Theriot, C.M., Inhibition of spore germination, growth, and toxin activity of clinically relevant C difficile strains by gut microbiota derived secondary bile acids. Anaerobe 45 (2017), 86–100.
75. Weingarden, A.R., Chen, C., Bobr, A., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306 (2014), G310–G319.
76. Buffie, C.G., Bucci, V., Stein, R.R., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.